POPULARITY
20 episodes with rpv
3 episodes with rpv
4 episodes with rpv
3 episodes with rpv
3 episodes with rpv
2 episodes with rpv
4 episodes with rpv
3 episodes with rpv
2 episodes with rpv
The Mountain Fire in Ventura County grows to 20,000 acres as dangerous winds batter the region. Jill Replogle updates us on the asbestos clean-up as Tustin marks one year since the hangar fire. The clock is ticking on home buyouts in RPV. Plus, more. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comSupport the show: https://laist.com
There's a new buyout programs for homeowners living in the Portuguese Bend neighborhood of RPV. UCLA baseball will get some access back to its stadium and practice field on the Veterans Affairs campus in West L.A. We continue our Spooky LA series with a trip to what some say is the most haunted building around: The Hotel Cecil. Plus more. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.com Support the show: https://laist.com
Witness saw plane go down in RPV but no planes have been reported missing / Liam Payne, member of One Direction / More Deli meat listeria // Creepy people behind home plate at Dodgers game / Starbucks making changes – cutting discounts / Jojo Wright 1027 KIIS on the death of One Direction's Liam Payne // Was it a plane or a UFO over RPV? // Bad news for Monkeys in Hong Kong
Michael Monks on the Menendez Brothers Presser // Steve Gregory recipient of Edward R. Murrow for LGBTQ+ Special // Report of plane crash Rancho Palos Verdes / Dodger Game 3 / Shohei Ohtani 50-50 ball going up for auction / WHIP: Elon Musk net worth $247 Billion / Cosm Event Venue // Dorito's After Dark / Possible plane crash in RPV
PROTECTING THE 2024 VOTE, & A WEBINAR ON NEW NUKES > > We start GREEP Zoom #193 with the great ANDREA MILLER, who lays out her powerful push for getting out the vote in key swing states, including Florida, Georgia and North Carolina. > > STEPHEN SPITZ explains his very mixed experience with young election workers at the University of Michigan. > > RAY MCCLENDON follows by describing the mixed impacts of manipulated polls and the stripping of voter registration rolls in Georgia and elsewhere. > > A major election outcome prediction made by Alan Lichtman, who has been right many times before, is analyzed by TATANKA BRICCA. > > > We then shift gears to our Nuclear Webinar, starting with Michigan-based reporter ROGER RAPOPORT, who gives us the low-down on the insane attempt to re-fire the Palisades atomic reactor. > > World-renowned health researcher JOE MANGANO confirms the death toll from TMI, Fermi, Palisades and other nukes linked to radiation emissions from these “perfectly safe” loser reactors. > KEVIN KAMPS of Beyond Nuclear adds Fermi I and other destroyed or decrepit nukes to the murderous list. We pay homage to the great Philadelphia Inquirer op ed against TMI from the great Jane Fonda. LINDA SEELEY from the San Luis Obispo Mothers for Peace updates us on the latest developments from Diablo Canyon, and reminds us that badly embrittled pressure vessel at Unit One is identical to the RPV at Palisades.. SHERI MCWHIRTER asks about the rule-making petition being circulated by Roger Rapoport. MYLA RESON reminds us of the steam generator disaster at San Onofre that forced that plant's permanent closure. Cleveland's CONNIE KLINE reports on the continuing energy disaster in Ohio. Santa Monica's PAUL NEWMAN asks about Betty Yee, a candidate for California governor who stabbed the renewables industry while she was on the Coastal Commission. LYNN FEINERMAN wonders if the fossil/nuke industry is using the “anti-woke” reaction to obstruct the rise of renewable energy worldwide. STEVE CARUSO wonders about the “crazy-whack” attack against renewables despite their plummeting price tag. Next week we will meet on Indigenous People's Day, hopefully to celebrate the release of LEONARD PELTIER.
In this episode of P4A Let's Talk Rare, hosts Georgie and Owen Bryant from Partners For Access are joined by Wes Michael, founder and president of Rare Patient Voice LLC. Wes shares the organization's journey from its beginnings as a community project for hemophilia patients to a global platform that connects rare disease patients and caregivers with healthcare professionals. Rare Patient Voice has awarded over $30 million to participants and completed more than 210,000 projects, with Wes highlighting the company's organic growth through patient referrals and advocacy partnerships. Wes discusses the challenges of reaching patients nationwide, the rewarding impact of patient involvement in healthcare, and the essential role of patient-centricity in shaping drug development and health technology assessments. He emphasizes that patients' voices, as the end-users, are critical for creating effective healthcare solutions. Looking ahead, Wes shares his enthusiasm for expanding Rare Patient Voice into clinical trials and increasing its presence in Europe. The episode concludes with a call to action for patients and caregivers to join the Rare Patient Voice community and share personal stories to further understanding and awareness of rare diseases. Wes Michael Bio: A market research industry veteran of over 40 years, Wes earned his MBA from the University of Chicago Booth School of Business and a BA in English from the University of Pennsylvania. In 2013, Wes launched Rare Patient Voice, based on a novel approach to building a market research panel that enables patients and caregivers to share their voices with researchers and companies developing products to improve patients' lives. He structured the company on the core values of being a good patient resource, a good client partner, a good employer to staff, and a good citizen in our community. Since then, Wes has seen the company grow, expanding from the US to Canada, the United Kingdom, Spain, Italy, France, and Germany, completing thousands of projects, and providing customized service to hundreds of clients. He hopes that RPV's work can help the lives of patients and caregivers who have participated in our studies and those who come after. Episode Resources: Wes Michael on LinkedIn Rare Patient Voice LLC Website Owen Bryant on LinkedIn Georgina Rack on LinkedIn Partners4Access Website P4A Let's Talk Rare podcast on Apple Podcasts
GUEST – Tim Lynn: Restricted flight zone for Trump over RPV when he comes to SoCal // Recapping the debate from last night. Debate betting was off the hook! // Keith Urban Album Release Party iHeartRadio Theatre giveaway // No one wants the Cherry Coke in the break room, except KiKi and Angel.
Jill need your support ‼️ I wanted to share this with everyone and ask for your support. As you know I am very passionate about my health, and advocating for adrenal insufficiency. I was recently approached by RARE PATIENT VOICE. RPV brings the gap between patients and researchers. Patients have voice by being giving the opportunity to participate in research. RPV gives you, the patient the opportunity and you can choose if it is right for you. No obligation. No pressure. Your choice. Always. This can be as simple as a survey to clinical trials. It is all up to the individual and many opportunities you get paid up to $125 US/hour. Please join me. Register here:https://www.rarepatientvoice.com/rp/thepicklejar It is pretty amazing and open to anyone with a diagnosed illness. You simply register. Takes about 3 minutes. RPV reaches out if there is an opportunity. You decided if you choose to participate. If you want change. If you want progress. You need to register and give yourself to oppoutniry to have your voice heard. Again this is open to anyone with a diagsnosed illness. ADRENAL INSUFFICIENCY patients desaparetly needed. Only 366 registered in US. Only 18 registered in Candaa Only 44 registered in the UK. All patients deserve to have a voice. Please join me. Register here:https://www.rarepatientvoice.com/rp/thepicklejar Please share this information and link with anyone you know who has an illness/diagnosis and give them the oppotunity to be part of change. This is very important to me so I truly hope you considering join me. Jill ❤️
BE PART OF THE VOICE OF CHANGE: https://www.rarepatientvoice.com/rp/thepicklejar Do you have an illness and what to be a voice for change⁉️ Do you want to make a difference⁉️ ‼️JOIN ME and RARE PATIENT VOICE‼️ We need to be heard! A few weeks ago THE PICKLE JAR PODCAST was contacted by RARE PATIENT VOICE. They requested to have their VP PAM CUSICK on the podcast to share RARE PATIENT VOICE. RPV is our voice with illness. RPV advcoates between researchers and patients to improve care and treatment. ‼️THIS IS WHAT WE NEED.‼️ It is simple. REGISTER with RPV (link up above) RPV contacts you with opportunity to participate in research from surveys, trials etc. YOU have the CHOICE to say YES or NO Many opportunities you get paid for your involvement. RPV wants to increase their patients with adrenal insufficiency BUT anyone with any diagnosed illness can register. THIS IS A POSITIVE step for people with adrenal insufficiency. PLEASE register and give yourself the opportunity to be part of our voice for change. ‼️You want to be heard....now it is time.‼️ Registering is simple and takes less then 3 minutes. Please share this link and message to everyone you know with adrenal insufficiency or an illness who wants to be heard. The amazing podcast with Pam will be released soon JOIN ME...and be part of the voice of change. You know it will save lives! FOLLOW THIS LINK: https://www.rarepatientvoice.com/rp/thepicklejar
RPV city leaders learn the slide is deeper and faster-moving than originally thought. Also this evening: Artificial Intelligence will help monitor bike lanes in Santa Monica; and California takes a central role at the DNC.
Tonix Pharmaceuticals CEO Seth Lederman speaks with with Proactive's Stephen Gunnion about the company's accelerated efforts to develop a single-dose vaccine for Mpox, TNX-801, in light of the World Health Organization's declaration of a global health emergency. Lederman highlighted the vaccine's promising results in animal studies, which showed protection against lethal challenges with Clade 1 Mpox virus and prevention of skin lesions, potentially blocking forward transmission. As the threat of more lethal strains like Clade 1 emerges, Tonix is ramping up its development process, focusing on producing GMP material suitable for human trials. The vaccine, based on Tonix's RPV platform, is designed for rapid distribution and could play a critical role in managing the public health crisis. Lederman also discussed the potential risks associated with Clade 1's spread beyond Africa, stressing the need for quick and effective solutions. With a single dose, this vaccine could provide a durable defense against Mpox, akin to vaccines for smallpox. The company's efforts reflect the urgency of the situation and the importance of innovative solutions in pandemic preparedness. Visit Proactive's YouTube channel for more videos, and don't forget to give this video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #MpoxVaccine #SethLederman #TNX801 #PublicHealth #WHO #Monkeypox #Biotech #Pharmaceuticals #PandemicPreparedness#ProactiveInvestors #InvestmentStrategy #ProactiveInvestors ##invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
A Primeira Seção do Superior Tribunal de Justiça decidiu não são devidos honorários de sucumbência em cumprimento de sentença não impugnado pela Fazenda Pública, mesmo que o crédito esteja submetido a pagamento por meio de requisição de pequeno valor. Essa decisão foi tomada em julgamento realizado sob o rito dos recursos repetitivos, cadastrada como Tema 1.190. Isso significa que ela vai servir de base para os demais tribunais do país, quando julgarem casos idênticos. O relator, ministro Herman Benjamin, propôs a modulação dos efeitos da decisão para que só sejam alcançados os cumprimentos de sentença iniciados após a publicação do acórdão do julgamento. Segundo o ministro, a jurisprudência anterior do STJ considerava que, nas hipóteses de pagamento da obrigação por meio de RPV, seria cabível a fixação de honorários nos cumprimentos de sentença contra o Estado, ainda que não impugnados. Contudo, ele afirmou que o tema merece uma nova análise diante do Código de Processo Civil de 2015. Herman Benjamin explicou que a regra é o pagamento de honorários no cumprimento de sentença e na execução, resistida ou não. No entanto, destacou que o parágrafo 7º do artigo 85 do CPC de 2015 traz uma exceção quando estabelece que não serão devidos honorários no cumprimento de sentença contra a Fazenda Pública que enseje a expedição de precatório, desde que não tenha sido impugnada. Na avaliação do ministro, essa regra também alcança o cumprimento de sentença com a expedição de RPV. Para ele, no cumprimento de sentença que impõe a obrigação de pagar quantia certa, os entes públicos não têm a opção de pagar voluntariamente.
Hallo zusammen! Es ist mal wieder an der Zeit, dem Podcast mit heiß aufgebrühten Themen quer durch die Bank zu begegnen – will sagen, ein Kaffeeklatsch steht an. Michael und Thomas sprechen über Themen aus der Verlagswelt wie auch direkt vom Spieltisch, sprechen über Fehler, Möbelstücke und das Leben an sich. Und obwohl's schon im Hauptteil ein wilder Mix aus Themen ist, gibt es sogar noch weitere Themen vor dem Thema dieses Mal. Und keine Frage, die Medienschau darf ebenso wenig fehlen wie Timecodes, weiterführende Links und Infos unten in den Shownotes. Viele Grüße, eure DORP 00:00:38 Intro 00:01:14 Feedback-Schleife 00:02:18 DORP-TV von der Feencon (und etwas spät hier genannt: auch von der RPV) 00:03:35 Thomas zu Gast im Nerdigen und Niveauvollen Trashtalk 00:04:46 Medienschau: The Last Kumite 00:14:22 Zum Kaffee! 00:14:30 Wie gehen wir bei der Charaktererschaffung vor? 00:15:43 Der Michael soll über Ponys reden! 00:17:50 Unsere Fails beim Meistern 00:19:46 Wie geht man mit Problemspielern um 00:23:43 Gamemaster as a Service 00:24:49 Wieso kommen bei Rollenspielbüchern manchmal so krasse Fehler zustande? 00:28:54 Handwerker und Händler im Rollenspiel 00:31:59 Haben wir eine Meinung zu Slice-of-Life-Games? 00:33:22 Unsere Meinung zu Luxus-Rollenspiel-Objekten wie etwa Wyrmwood-Tischen 00:37:55 Unsere Meinung zu Fitness und Gesundheit 00:41:01 Ist Rollenspiel Kunst? 00:43:06 Was ist das Wichtigste im Leben? 00:43:35 Ausklang 00:43:43 Sermon 3.6 00:44:45 Adieu! 00:45:24 Der Nach-Teil
In 2013, Wes founded Rare Patient Voice to provide patients and their caregivers with the opportunity to voice their opinions through surveys and interviews to improve medical products and services. As with any new business, the initial days were challenging. Wes knew that he wanted to be able to share this resource with all clients, so he purposely did not accept investments from clients or other related sources. He spent time traveling across the country and meeting patients and caregivers at events such as awareness days, fundraising walks, meetings, and conferences. Eventually, the business grew and Wes was able to add staff to support projects and attend events.Wes has been amazed at the great reception Rare Patient Voice has received from both patients and the market research industry. To date, over $13 million dollars have been awarded to RPV participants. Working to meet the needs of advertising agencies, market research firms, pharmaceutical companies and other clients has been a labor of love for this longtime marketing professional. In addition to the United States, Rare Patient Voice now recruits patients and caregivers for studies in Canada, the United Kingdom, Germany, France, Italy, Spain, Australia, and New Zealand.
In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the newest data supporting LA ART use in people with adherence challenges or viremia, including:The LATITUDE study, an open-label phase III study of LA CAB + RPV in people with a suboptimal response or nonadherence to oral ARTUpdates to the Ward 86 cohort, which showed 81% of patients with viral suppression on LA CAB + RPV at Week 48The CARES study, an open-label, noninferiority phase IIIb study of LA CAB + RPV in people with baseline resistance mutationsPresenter:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier, Jr., MD Education Director and Professor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineMedical DirectorCare Point Health and WellnessTallahassee, FloridaLink to the full program:https://bit.ly/49x0W6DLink to the slideset: https://bit.ly/4bzZothTo get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
Wes Michael is the founder and CEO of Rare Patient Voice, a 10-year old firm who empowers patients and caregivers to share their voices with the companies working to better their lives with new products, devices, and treatments. [To date, RPV has paid out over $13M in incentives to patients and caregivers – wow!!]Wes started RPV after a successful research and brand management career at General Mills and McCormick and later with Kantar Health.He shares his novel approach to starting RPV and the mutual benefits of RPV to both patients and companies. He also discusses his quirky approach to marketing which has him singing customized lyrics set to familiar tunes like The Beverly Hillbillies theme and 9 to 5 by Dolly Parton.
In this episode, Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the key HIV studies from CROI 2024 that are influencing their clinical practice, including:New data surrounding long-acting ART, including:The CARES study of LA CAB + RPV in a Sub-Saharan African population using a public health approachThe IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIVThe ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ARTUpdated data from San Francisco's Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baselineCase series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV aloneData on comorbidities and coinfections, including:A REPRIEVE proteomic analysis to elucidate mechanistic pathways of statin effects on plaqueThe ACTG A5371 SLIM LIVER study of semaglutide for MASLD in people living with HIVThe impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San FranciscoPotential novel treatment options on the horizon for people living with HIV, including:Phase II data on LEN + ISL dosed orally once weeklyEarly data on other oral weekly optionsData on bNAbs in combination or with other ART agentsPresenters:Joseph J. Eron, Jr., MDProfessor of Medicine, School of MedicineHerman and Louise Smith Distinguished ProfessorChief, Division of Infectious DiseasesDirector, Clinical Core, UNC Center for AIDS ResearchAdjunct Professor of EpidemiologyGillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineMedical Director, Ward 86 HIV ClinicUniversity of California, San FranciscoSan Francisco, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.Link to full program: https://bit.ly/4awdWJMGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
Investing in a website that is not optimized for conversions is like pouring water into a leaky bucket with a hole in it. You are likely spending thousands of dollars on your digital marketing efforts, all to have your website not properly optimized to convert that traffic into buyers. Acquiring traffic is becoming increasingly expensive and competitive every single day. With the increased cost of customer acquisition, it's crucial that your brand converts as many visitors into buyers as possible. That's where ThrillX comes in. We are a Canadian-based UX/UI Design and Conversion Rate Optimization agency helping eCommerce and B2B brands improve conversion rates without even touching your ads. We put you in a position to scale your marketing efforts so that when you receive more traffic, the revenue you generate is amplified. How do we do it? We have a unique data-driven and repeatable conversion optimization process that we use to increase your conversion rates and all your KPIs (AOV, RPV, etc) sustainably over time. Our process combines our expertise in human psychology and behavioral science with analytics tools such as heatmaps, scroll maps, user-testing, surveys, A/B testing, custom landing pages, and customer interviews to identify pain points and motivations. Every decision we make is based on real data and statistics, eliminating the guesswork and maximizing results. Here are some past client results: → Increased Influence Hunter's form inquiries by 385% → Increased Wild Man Drinking's e-commerce purchases by 97%, AOV by 13.5%, and delivered 5X ROI in just a few months → Increased apparel conversions for Optimal Sports Management by 115% → Increased Fiddler's Green CBD's product sales by 67% in just 1 month To schedule a free website audit and strategy session, use the link below: https://calendly.com/arshsanwarwala/30min
Pam Cusick is an esteemed research professional with over 30 years of experience in study design, implementation, and analysis. Pam's journey in public health communications and research has been driven by her unwavering passion for patient advocacy, a passion that seamlessly aligns with Rare Patient Voice's mission and vision.As the Senior Vice President of Rare Patient Voice, Pam spearheads initiatives aimed at expanding the organization's panels to encompass all patients and caregivers eager to share their insights and influence their disease categories. Her dedication to amplifying patient voices is evident in her focus on the continued growth and success of RPV.Enthusiastically, Pam engages with patients and caregivers at various conferences and events, where she educates them about Rare Patient Voice's mission. When individuals express uncertainty about the value of sharing their experiences, Pam passionately assures them of the significance of their unique perspectives. You'll learn how public health research informs Pam's advocacy, how patients are empowered by sharing their stories, and why DEI is thriving in healthcare advocacy.LEARN MORE:>>www.rarepatientvoice.comNSLS MEMBERS ONLY:>>Listen to the bonus episode to learn how our community benefits from us all sharing our stories and why clinical research benefits from more inclusivity of patients. (https://thens.ls/3TjhSXt)Mentioned in this episode:Get 20% Off at the NSLS ShopUse code MONDAYS for 20% your entire purchase at shop.nsls.orgNSLS Shop
This show is actually the prequel to last weeks show ( episode 14 ) ‘ Optimize the Regular Patient Visit'. Last week we discussed the solutions / answers to RPV optimization. This week, we'll discuss the reasons less successful doctors SAY they don't want to that. (AKA : Handling the objections some doctors put up that minimized their own success :-)
We can all agree, the thing we do most often is the regular patient visit. But, how do we optimize it for the patient and the practice? On this episode, we'll talk about how to make it a true WIN-WIN! When we optimize the RPV, not only do patients get great results, you'll have more fun in practice and the practice grows.
A Primeira Seção do Superior Tribunal de Justiça decidiu que o pedido de expedição de novo precatório ou de requisição de pequeno valor está sujeita ao prazo prescricional de cinco anos. De acordo com o colegiado, o marco inicial da contagem do prazo é a notificação do credor. O artigo 2º da Lei 13.463/2017 cancelou os precatórios e as RPVs federais cujos valores não tenham sido levantados pelo credor e que estejam depositados há mais de dois anos em instituição financeira oficial. Mesmo com o cancelamento, o credor pode requerer a expedição de nova ordem de pagamento, conforme estabelecido no artigo 3º da mesma lei. A relatora, ministra Assusete Magalhães, lembrou que o Supremo Tribunal Federal declarou a inconstitucionalidade material do artigo 2º dessa norma, produzindo efeitos a partir da publicação – o que ocorreu em 6 de julho de 2022 – mantendo, assim, o cancelamento anterior de inúmeros precatórios e RPVs. Contudo, o artigo 3º da Lei 13.463 não foi impugnado e tampouco a corte suprema se manifestou sobre a prescrição do direito de requerer a expedição de novo precatório ou RPV. Quanto a este último ponto, Assusete Magalhães reconheceu que há divergências entre os colegiados da Primeira e Segunda Turmas do STJ, já que a Primeira considera que não haveria prescrição para nova solicitação de expedição de precatório ou RPV cancelados, e a Segunda considera que seria aplicável o prazo prescricional a esses casos. A relatora destacou que, conforme previsto no artigo 1º do Decreto 20.910/1932, as dívidas do poder público, assim como qualquer direito ou ação contra a Fazenda federal, estadual ou municipal, estão sujeitas ao prazo prescricional de cinco anos. Esse entendimento foi firmado em julgamento realizado sob o rito dos repetitivos e foi cadastrada como Tema 1.141. Isso significa que ele servirá de base para os demais tribunais do país, quando julgarem casos com idêntica questão. Agora, poderão voltar a tramitar os processos individuais e coletivos, em segunda instância ou no STJ, nos quais havia sido interposto recurso especial ou agravo em recurso especial com a mesma questão jurídica. As ações estavam suspensas, por determinação do STJ, até a definição do precedente qualificado.
Hallo zusammen! Wer kennt es nicht – man sieht einen Film, man liest ein Buch, spielt ein Videospiel und denkt sich ‘Ey, das wäre eigentlich auch genau das Richtige für den Spieltisch!' Aber ist es so einfach? Michael und Thomas spüren heute aus sehr unterschiedlichen Perspektiven einmal dieser Idee nach, andere Medien für den Spieltisch zu adaptieren. Auch heute gibt es wieder ein paar Themen vor dem Thema, die gewohnte Medienschau, und wie eh und je Timecodes, weiterführende Links und Infos in den Shownotes! Viele Grüße, eure DORP 00:00:29 Intro 00:01:05 Feedback-Schleife 00:01:33 Der Scorp war auf der DreieichCon 00:05:13 Es war die RPC, lang lebe die (das?) RPV! 00:06:44 Patreon-Geld kauft Kopfhörer 00:07:26 Thomas (demnächst) zu Gast im Nerdigen & Niveauvollen Trashtalk 00:08:01 Medienschau: Gen V 00:11:53 Medienschau: Disco Eylsium 00:18:52 Zum Thema? 00:19:26 Zum Thema! 00:20:06 Michael sieht das easy 00:21:05 Wo setzt man an? 00:21:45 Ein Risiko beim Ausborgen von Plotstuktur 00:22:59 Was macht eine gute Vorlage aus? 00:24:20 Wiedererkennung muss kein Nachteil sein 00:25:21 Die Idee vs. den Inhalt adaptieren 00:28:39 Sich die Stärken des Mediums zueigen machen 00:31:04 Linear vs. nonlinear 00:33:44 Narrative um eine einzelne Heldenfigur 00:36:52 Der Wegfall der visuellen Komponente 00:38:18 Wie Thomas sowas angeht 00:39:47 Letzte Gedanken zum Thema 00:40:34 Sermon 3.6 00:41:13 Adieu 00:41:48 Der Nach-Teil
Providing Patients and Caregivers a Voice Rare Patient Voice connects patients and caregivers with the opportunity to voice their opinions through surveys and interviews to improve medical products and services. For patients and family caregivers —they provide study opportunities to voice their opinions on medical products and services while getting paid for their time. Sign up here. For patient advocacy groups —they partner with advocacy and support groups to increase donations. For market research firms —they handle patient recruitment and help find the respondents and patient panels needed for marketing research. For pharmaceutical and biotech companies —they provide the respondents and patient communities required to support business insight needs and all types of research studies. Pam Cusick, Rare Patient Voice's Senior Vice President, is an experienced research professional with more than 30 years of expertise in study design, implementation, and analysis. Her background in public health communications and research, coupled with her passion for patient advocacy, dovetail with Rare Patient Voice's mission and vision. She hopes to expand Rare Patient Voice's panels to include all patients and caregivers who want to share their opinions and impact their disease category. Pam earned a BA in Psychology from Sweet Briar College and an MA in Psychology from the New School for Social Research. Pam is past president of the Board of Directors and Scientific Advisory Council Lead for the Horses and Humans Research Foundation. As Senior Vice President, her focus is on the continued growth and success of RPV, with an eye on client services, business development, and oversight of outreach and panel management, marketing, and human resources. Learn more: Website: https://rarepatientvoice.com/ FB: @RarePatientVoice Twitter: @rarepatientvoic IG: rarepatientvoice Email: ContactUs@RarePatientVoice.com Link to Transcript: https://docs.google.com/document/d/1B8_llq6kLTdQp9c4AWMOaUKs6hnYfv20YFqNK7S_plg/edit?usp=sharing As an Amazon Associate, I earn commissions from qualifying purchases. For more information about True North Disability Planning you can find us here: Web: https://truenorthdisabilityplanning.com/ Waypoints - https://waypoints.substack.com/ Facebook: @TrueNorthDisabilityPlanning X (Twitter): @NeedsNavigator --- Send in a voice message: https://podcasters.spotify.com/pod/show/abcs-disability-planning/message Support this podcast: https://podcasters.spotify.com/pod/show/abcs-disability-planning/support
According to a BCG report, only 19% of VCs have some kind of scientific or technological competence. And that creates a translation problem between deep tech founders and investors. To close that gap, Arkady Kulik and his cofounder, Tamaz Khunjua, built RPV, a venture fund that brings scientific expertise to the market and helps scientists become strong entrepreneurs. On this episode of The Boost VC Podcast, Arkady joins us to explain how the RPV team's extensive background in science and entrepreneurship serves deep tech startups. Arkady describes how starting a venture fund differs from founding other companies and shares his excitement around ‘being at the edge of science' as a frontier tech VC. Listen in for Arkady's unique take on what it means to be useful to others and learn how RPV is working to make talented scientists billionaires! Topics Covered The idea behind RPVHelp scientists become strong entrepreneurs‘Commercialization of science' How Arkady got into venture capitalMoved to US to be part of scientific exploration of humanityLack of funding in prototyping stage of deep tech startups Arkady's biggest accomplishment before age 20Launched first company at 18 without external investmentScaled to annual revenue of $5M in third year How starting a venture fund differs from starting other companiesMore competitive, thousands of similar funds raising moneyHarer to differentiate and properly tell story of niche What part of being a VC Arkady enjoys the mostBeing at edge of science and meeting interesting peopleFinding processes that make things work The secret skills Arkady is most proud ofDeveloped extreme level of disciplineExtremely organized in managing time and data How Arkady thinks about being useful to othersProvide with relevant information or connectionsPut smile on someone's face, make life better The most valuable thing RPV provides for deep tech startupsExternal proof point for science and technologyEntrepreneurial experience and change management Arkady's ‘deathbed test' to measure successNothing ‘could have but didn't achieve'Self-actualization (happy, complex person) Connect with Arkady Kulik RPV https://rpv.global/RPV on LinkedIn https://www.linkedin.com/company/rpvglobal/Arkady on LinkedIn https://www.linkedin.com/in/arkady-kulik/Arkady on X https://twitter.com/arkadykulik Resources Starburst Aerospace https://starburst.aero/Cantos VC https://cantos.vc/Countdown https://countdown.capital/Fifty Years https://fiftyyears.com/Productivity Planner https://www.intelligentchange.com/products/productivity-plannerTerraforming Mars https://www.fryxgames.se/games/terraforming-mars/Breakfast with Pops: A Venture Capital Handbook by Adam Draper and William H. Draper III https://www.amazon.com/Breakfast-Pops-Venture-Capital-Handbook/dp/B0C1JHXTQF Connect with Boost VC Boost VC Website https://www.boost.vc/Boost VC on Facebook https://www.facebook.com/boostvc/Boost VC on X https://twitter.com/BoostVCBoost VC on Instagram https://www.instagram.com/boost_vc/
Welcome to our summer series. You probably noticed a change in the intro right? Lol. We believe summer should be full of fun, good vibes, and great tunes! Was Michael A founded Rare Patient Voice in 2013 to give patients and family caregivers with rare diseases, the opportunity to voice their opinions and research studies. This year the company celebrates its 10th anniversary. Rare Patient Voice has now conducted thousands of studies and rewarding patients and family caregivers with over $10 million dollars for their participation. Many have been recruited in person by West himself at patient events and through a robust referral program with patient advocacy and support groups. Rare Patient Voice now covers non-rare as well as rare diseases and conditions and has expanded from the United States to Canada, the United Kingdom, France, Germany, Italy, Spain, Australia, and New Zealand Before launching Rare Patient Voice, Wes worked for healthcare market research firm Cantar health. He previously was a brand manager in marketing research manager at McCormick, the spice Company, and General Mills, working on Wheaties, total and kix cereals. He has a BA from the University of Pennsylvania and an MBA from the University of Chicago. I like to think of Wes, regardless of all his many accolades, as just another good dude and rare patient advocate. He is helping the community through one research study at a time. You can find Wes and the RPV team through these social media platforms: Website: https://rarepatientvoice.com Facebook: https://rarepatientvoice.com Insta: https://www.instagram.com/rarepatientvoice Linkedin: https://www.linkedin.com/company/rare-patient-voice
Ron talks with Wes Michael who founded Rare Patient Voice (RPV), a company that enables patients and caregivers to share their voices with the researchers and companies developing products to improve patient's lives. RPV provides patients and caregivers an opportunity to participate in all types of research, including market research, health economics outcomes, real world evidence, user experience, human factor studies and clinical trials. RPV has over 100,000 patients and caregivers across more than 700 diseases both rare and non-rare. Sponsors: Hero Soap Company-Use code RAP for 10% discount www.herosoapcompany.com Blue Sky CBD Use the link below or Promo Code RON for a 20% discount https://www.bluesky-cbd.com/pages/_go_?ref=3251:615856&discount=ron Feel Good Knees Method https://f75bdd6-s9sk9vdkb93locvr9j.hop.clickbank.net Links: Rare Patient Voice https://rarepatientvoice.com/itsawrapwithrap contactus@rarepatientvoice.com https://itsawrapwithrap.com #HC Univrersal Network
Ron talks with Wes Michael who founded Rare Patient Voice (RPV), a company that enables patients and caregivers to share their voices with the researchers and companies developing products to improve patient's lives. RPV provides patients and caregivers an opportunity to participate in all types of research, including market research, health economics outcomes, real world evidence, user experience, human factor studies and clinical trials. RPV has over 100,000 patients and caregivers across more than 700 diseases both rare and non-rare. Sponsors: Hero Soap Company-Use code RAP for 10% discount http://www.herosoapcompany.com Blue Sky CBD Use the link below or Promo Code RON for a 20% discount https://www.bluesky-cbd.com/pages/_go_?ref=3251:615856&discount=ron Feel Good Knees Method https://f75bdd6-s9sk9vdkb93locvr9j.hop.clickbank.net/ Links: Rare Patient Voice https://rarepatientvoice.com/itsawrapwithrap https://rarepatientvoice.com https://itsawrapwithrap.com #HC Univrersal Network
In this episode, Ian Frank, MD, discusses long-acting HIV treatment with cabotegravir plus rilpivirine for people with HIV, including:Efficacy data with every-8-week dosingReal-world use in people with viremia Initiation and continuation strategiesVirologic failure dataSafety information Presenter:Ian Frank, MDAssociate ChiefDivision of Infectious DiseasesProfessor of MedicineUniversity of PennsylvaniaPhiladelphia, PennsylvaniaTo download the slides: https://bit.ly/3HX1GGn To view the full online program: https://bit.ly/3ZjSFhg
Brad Redding, Founder & CEO @ Elevar (Connect on LinkedIn and Twitter) shares 5 specific examples of onsite conversion optimization improvements and the underlying data behind them. Brad also shares how to calculate the data behind a UX issue we found that could make a customer an extra $50K/month. Plus you'll learn about Elevar's new public Benchmark that charts key metrics like conversion rate, RPV, and others by revenue band, vertical, and date range. -----We release new episodes every week that go deep into the world of tracking, analytics, and conversion optimization.-----Links Referenced:Elevar Index BenchmarkPlus Stores -- How to maintain tracking when upgrading to checkout extensibilityGA4 event tracking setup tipsTrue Classic TeesElevar Changelog-----And if you're new to Elevar, Elevar automates server-side conversion tracking for Shopify. Check us out!
In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)Optimizing the use of the Antiretroviral Pregnancy RegistryAddressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)Faculty: Jill Blumenthal, MD, MASAssociate Professor of MedicineInfectious Diseases and Global Public Health University of California, San DiegoSan Diego, CaliforniaWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious Diseases Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia, PennsylvaniaLink to full program:http://bit.ly/3PM3nYeLink to downloadable slides: http://bit.ly/3WgYycz
Precatório: o instrumento para pagamento de débito do ente público. Quebre o preconceito e encare uma nova oportunidade! Neste novo episódio do Direito Fora de Pauta, talvez o mais longo de toda a série, falaremos do precatório judicial, aquela ordem judicial pra pagamento de débitos pelos entes públicos. ATENÇÃO! Você que já ouviu falar, mas não tem a mínima ideia de como funciona; Você que quer fugir desesperadamente desta espécie de pagamento! Você que tem precatório já constituído e aguarda a sua vez de receber! Você quer quer enxergar uma nova oportunidade e área nova pra aumentar seus ganhos mensais! ESSE EPISÓDIO É PRA VOCÊ! - O que é um precatório? - Como são organizados os pagamentos? - Como funciona a fila de pagamento? - Como funciona a fila preferencial? - Qual a diferença para a RPV? - Por que pode ser uma nova oportunidade de potencialização dos ganhos mensais? O episódio mais completo e mais detalhado sobre tema e que promete ramificações abordado sempre formato descontraído e descomplicado e repleto de humor pelos advogados, Fábio Carvalho, Caio Almeida e com a presença ilustre de uma das maiores autoridades no país sobre o tema, o tributarista Felipe Cunha! *Obs: opinião pessoal de Fábio Carvalho - “o melhor episódio de todos os tempos” Vem com a gente! Avalie, critique, curta, compartilhe e nos marque nas redes sociais! Apresentação, direção e roteiro: Advogados Fábio Carvalho e Caio Almeida. Convidado: Felipe Cunha. Sigam nossas redes sociais: Instagram, TikTok, Twitter, Canal do Youtube e Facebook: @direitoforadepauta . Email: direitoforadepauta@gmail.com NÃO PERCAM!
In this episode, Eric Florence, MD, PhD, discusses how clinics can prepare for the implementation of long-acting injectable antiretroviral therapy, including:Clinical infrastructureEnsuring adequate space and injection equipmentMaintaining drug supply and temperature requirementsStaffingEnsuring there are staff able to focus on the implementation of LA ART, including well-trained nurses to administer the injectionsImplementing a system for scheduling follow-up injections and providing patient remindersHaving knowledgeable staff available to answer patient questions on their LA ARTEric Florence, MD, PhDPhysicianInternal Medicine, Infectious Diseases & Tropical MedicineUniversity Hospital of AntwerpEdegem, Brussels, BelgiumSee the full program at: https://bit.ly/3CsSvdX
In this episode, Laurence Slama, MD, PhD, describes some of the ways that her clinic is attempting to make IM injections of long-acting antiretroviral therapy more sustainable long term. She explains the logistics of how she has allowed for patients to receive their long-acting cabotegravir and rilpivirine doses through community nurses after receiving the first 3 doses in a clinical setting. She also discusses some of the benefits and challenges of this kind of flexible system for patients and healthcare professionals. Laurence SlamaDoctorDepartment of Infectious DiseasesHôtel Dieu, APHPParis, FranceSee the full program at:https://bit.ly/3CsSvdX
In this episode, Stephane De Wit, MD, PhD, discusses the benefits of long-acting antiretroviral therapy (ART) for migrant populations in Europe—and specifically in Belgium. He also addresses some of the challenges of accessing and following up with those populations.Dr De Wit describes some of the ways that the Belgian healthcare system is set up to improve access to ART. He then explains some of the disease parameters for considering expanding the use of long-acting ART to patients who are not virologically suppressed. Finally, Dr De Wit offers some thoughts about the future of long-acting ART to migrant populations in Belgium.Stephane De Wit, MD, PhDFormer HeadInfectious DiseasesSaint Pierre University HospitalBrussels, BelgiumSee the full program at:https://bit.ly/3HIMAoF
In this episode, Annette Haberl, MD, and William R. Short, MD, MPH, AAHIVS, discuss when to consider an ART switch during pregnancy, including:Current DHHS, EACS, WHO, BHIVA, and German/Austrian guidelines for the use of ARVs in pregnancyWhat data and recommendations for the use of ARVs during pregnancy are currently missing from the guidelinesAvailable data on newer ARVs in the ARV pregnancy registryPharmacokinetic data for newer ARVs including BIC/FTC/TAF and LA CAB + RPV in pregnancyRecommendations for 2-drug ART regimens in pregnancyWhat to do when someone becomes pregnant on a newer ART regimen that is not yet recommended by the guidelinesAnnette Haberl, MDPhysicianHead of HIV and WomenHIVCENTER FrankfurtDepartment of Infectious DiseaseHospital of the Johann Wolfgang Goethe UniversityFrankfurt, GermanyWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3HPu4Lk
In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including: Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)Risk factors for virologic failure of LA CAB + RPVThe ATLAS-2M studyCombined clinical trials of LA CAB + RPVPractical considerations for LA CAB + RPVImplementation of LA CAB + RPV Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension studySupporting candidates for LA antiretroviral therapy (ART)Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San FranciscoFuture LA ART The investigational LA HIV capsid inhibitor lenacapavir (LEN)LEN resistance from the CAPELLA and CALIBRATE studiesLEN injection-site reactions in the CAPELLA and CALIBRATE studiesPresenter: Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program:https://bit.ly/3VIsDTgFollow along with the slides at:http://bit.ly/3Gh9AKG
When you should you say no to a customer? Wes Michael shares a wealth of thought this subject and why you should think about it first. A market research industry veteran of over 40 years, Wes earned his MBA from the University of Chicago Booth School of Business and a BA in English from the University of Pennsylvania. In 2013, Wes launched Rare Patient Voice based on a novel approach to building a market research panel, one that enables patients and caregivers to share their voices with the researchers and companies developing products to improve patients' lives. He structured the company on the core values of being a good resource for patients, a good partner to clients, a good employer to staff, and a good citizen in our community. Since then, Wes has seen the company grow, expanding from the US to Canada, the United Kingdom, Spain, Italy, France, and Germany, completing thousands of projects, and providing customized service to hundreds of clients. He hopes that RPV's work can help the lives of patients and caregivers who are able to participate in our studies, and of those who come after. Hobbies: Walking his dogs, piano, history, exercise Pets: Ace (mix of Beagle and Brittany) and Stanley the Chocolate Lab Likes: Hearing from patients who have enjoyed taking part in a study Dislikes: When no one qualifies for a study Fun Facts: Wes spent a year in Edinburgh, Scotland and ran cross country with the Hare & Hounds MAIN TAKEAWAYS: “You need to have a folder somewhere… where you say: IDEAS (...) Don't loose track of these things” “Deadlines are important. We work towards deadlines. But you can negotiate, you can talk to them, let them know...” “You've got to look at what's the fair amount. Somebody doesn't deserve all of your time.”
In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:Switching with prior or unknown resistanceData on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studiesThe impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 studyA post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistanceData from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184VA retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat'AIDS CohortSwitching to long-acting ARTGuidance on candidates for LA CAB + RPVData on risk factors for virologic failure with LA CAB + RPVConsidering an ART switch after weight gainData on weight gain after ART initiation by ARV class and drugMean change in weight by sex at Week 96 in the ADVANCE studyDHHS guideline recommendations regarding weight gain with ARTTristan J. Barber, MA, MD, FRCPHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonConsultant in HIV MedicineIan Charleson Day CentreRoyal Free HospitalLondon, United Kingdom Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, California
It's operation Askari, and 61 Mech's has fulfilled the first part of the plan, driving FAPLA out of Quiteve and now were approaching Cahama, which is 96 kilometers north west of Xangongo. This was going to be a tough nut to crack. FAPLAs second Brigade was ensconced in strongly fortified positions to the north and south of the town. The defenders had become used to SADF and SA Air Force attacks, if you remember during Operation Protea the Air Force had hammered radar installations at Cahama and the Recces spent a lot of time around the little town. So after years of battering, defences had been beefed up, bunkers were deeper, heavier weapons abounded. Busy in the air through most of November and December 1983 was the SA Air Force's Garrha Remote Piloted Vehicle, or drone, and it had discovered the location of enemy SA8 missile systems. The photographs were blurry, but the location was clear. They were in positions around the town. Brigadier Joop Joubert who commanded all SADF forces during Askari expected these defenders to wilt as the pressure rose through December and into January 1984 – he just needed time to do – and time was not on his side. However, in what turned out to be a jaw-dropping miscommunication, the planners forgot to inform the Air Force about Combat Team Delta Foxtrot, which was about 45km south west of Caiundo on the western bank of the Cubango River. That was about 130km east of the main target of Cuvelai, and even in a Puma or a Mirage, that's a long way to go to offer support. On the 23rd of December and about 2 kilometers west of Cahama, the SA Air Force drone was damaged by shrapnel from an SA-8 ground to air missile. The operators managed to keep the RPV in the air and it headed back to Xangongo where it landed safely.
It's operation Askari, and 61 Mech's has fulfilled the first part of the plan, driving FAPLA out of Quiteve and now were approaching Cahama, which is 96 kilometers north west of Xangongo. This was going to be a tough nut to crack. FAPLAs second Brigade was ensconced in strongly fortified positions to the north and south of the town. The defenders had become used to SADF and SA Air Force attacks, if you remember during Operation Protea the Air Force had hammered radar installations at Cahama and the Recces spent a lot of time around the little town. So after years of battering, defences had been beefed up, bunkers were deeper, heavier weapons abounded. Busy in the air through most of November and December 1983 was the SA Air Force's Garrha Remote Piloted Vehicle, or drone, and it had discovered the location of enemy SA8 missile systems. The photographs were blurry, but the location was clear. They were in positions around the town. Brigadier Joop Joubert who commanded all SADF forces during Askari expected these defenders to wilt as the pressure rose through December and into January 1984 – he just needed time to do – and time was not on his side. However, in what turned out to be a jaw-dropping miscommunication, the planners forgot to inform the Air Force about Combat Team Delta Foxtrot, which was about 45km south west of Caiundo on the western bank of the Cubango River. That was about 130km east of the main target of Cuvelai, and even in a Puma or a Mirage, that's a long way to go to offer support. On the 23rd of December and about 2 kilometers west of Cahama, the SA Air Force drone was damaged by shrapnel from an SA-8 ground to air missile. The operators managed to keep the RPV in the air and it headed back to Xangongo where it landed safely.
We review a 1976 Lockheed Missiles $ Space Company report that NASA commissioned. The report is 328 pages, is very comprehensive, and includes uses, cost-benefit analysis, safety information, FAA regulatory needs, and certification. It was all supposed to happen by the mid-1980s. What didn't happen?
By November 1983 the SADF was prepping for the significant operation called Askari, and the Air Force was playing its part. The original plan was for the op to start on the 9th November but political negotiations had led to a postponement to the 9th December. Meanwhile, the SA Air Force had sent up their remotely piloted vehicle or RPV– in Xangongo under Major Jinx Botes. The aim was to monitor the Cahama area initially as part of a sub-Askari operation called Fox . The RPV was code-named Gharra and was trying to detect the location of SA-8 missile systems sent to the South by the Angolans – courtesy of the Russians. It proved a rather hit and miss process, these were early days in the use of what we now know as drones. Time to take a closer look at Operation Askari which was broken into four phases. First, the Special Forces would recce deep into Angola, then the SA Air Force would bomb the Typhoon and Volcano base near Lubango. Phase 2 would see offensive reconnaissance around Cahama, Mulondo and Cuvelai and the SADF estimated this could take as long as two months, starting at least a week after phase 1 had kicked off. The main aim was to cut off SWAPO and FAPLAs communication and logistics lines, and to demoralize the SWAPO sections leading to their withdrawal north. However, the SADF missed a crucial bit of information when assessing their options in phase two – they presumed both FAPLA and SWAPO morale was low, but that was not the case. It was higher than it had been for years. SWAPO's PLAN armed wing had been withdrawn into Angola for retraining. And These fighters were briefed about the new heavy weapons sent by the Russian sponsors - including T54/55 tanks – as well as the new missile systems. Demoralizing them this time was not going to be as easy as in 1981. Phase three which was to begin after the invasion was to reinforce the gaps supposedly created by Askari west of the Cunene River, through Quiteve, Mupa, Vinticette and then to Ionde. The last phase was to reinforce the empty bases once SWAPO and FAPLA left, and thus stop this year's incursions into SWA.
By November 1983 the SADF was prepping for the significant operation called Askari, and the Air Force was playing its part. The original plan was for the op to start on the 9th November but political negotiations had led to a postponement to the 9th December. Meanwhile, the SA Air Force had sent up their remotely piloted vehicle or RPV– in Xangongo under Major Jinx Botes. The aim was to monitor the Cahama area initially as part of a sub-Askari operation called Fox . The RPV was code-named Gharra and was trying to detect the location of SA-8 missile systems sent to the South by the Angolans – courtesy of the Russians. It proved a rather hit and miss process, these were early days in the use of what we now know as drones. Time to take a closer look at Operation Askari which was broken into four phases. First, the Special Forces would recce deep into Angola, then the SA Air Force would bomb the Typhoon and Volcano base near Lubango. Phase 2 would see offensive reconnaissance around Cahama, Mulondo and Cuvelai and the SADF estimated this could take as long as two months, starting at least a week after phase 1 had kicked off. The main aim was to cut off SWAPO and FAPLAs communication and logistics lines, and to demoralize the SWAPO sections leading to their withdrawal north. However, the SADF missed a crucial bit of information when assessing their options in phase two – they presumed both FAPLA and SWAPO morale was low, but that was not the case. It was higher than it had been for years. SWAPO's PLAN armed wing had been withdrawn into Angola for retraining. And These fighters were briefed about the new heavy weapons sent by the Russian sponsors - including T54/55 tanks – as well as the new missile systems. Demoralizing them this time was not going to be as easy as in 1981. Phase three which was to begin after the invasion was to reinforce the gaps supposedly created by Askari west of the Cunene River, through Quiteve, Mupa, Vinticette and then to Ionde. The last phase was to reinforce the empty bases once SWAPO and FAPLA left, and thus stop this year's incursions into SWA.
We're baaaaaack!Step back in the ring with RPV for Wrestlemania X8!It's icon vs icon, brevity vs elder abuse, Tim Curry vs SPACE!
Medical researchers have FINALLY realized something that we in the chronic illness space have known for a while - that the true experts are not necessarily those who have studied a condition but are in fact those of us who live with a condition 24 hours a day, seven days a week, 365 days a year. Due to this realization, researchers now want to include our voices (as well as those of our family caregivers) in their studies. And we are getting paid for our time and input. Because it can be difficult to connect with patients and caregivers, there are organizations that exist to join the dots. One of these is Rare Patient Voice (RPV), and my guest today is Mel Havert, the Patient Outreach Manager for RPV. Mel's role is based around connecting with patients and caregivers, and inviting them to the RPV panel so that they can assist with research opportunities and make their voices heard.Listen in to find out how you can be involved, improve medical research, and get paid for your time and experience!In this episode:What is Rare Patient Voice and what does it do?How patients can join and how the RPV process worksThe key question - how much patients can be paid?!What RPV does (and doesn't do) with your personal data How patients can sign up to RPV via the PGP affiliate linkFull notes and resources at https://patientsgettingpaid.com/blog/paid-research-patient-experience
USAFA - Spirit of 76 - Legacy Project - REPORT! Interviews with the Long Blue Line.
Bryce is the son of a 79 Grad and as a cadet was noteworthy as a KAFA DJ, Recondo instructor, and Poly Sci major. IN USAF he became a C-130 and RPV pilot spending much time in the desert, Nevada and SW Asia. At the time of this interview Bryce is living with his family in Omaha an still in the USAF Reserves. He has quite the update on doolie year for us older coots.
Stepping up to the dish today is none other than Joseph Pisapia… or as some of you may know him, the ying to my yang in the fantasy space. Joe is the creator and writer for the Fantasy Black Book series as well as show host at FantasyPros as well as over at SportsGrid. Our host Dan Strafford and Joe discuss head to head points and all play, the Fantasy Black Book, RPV, pitcher markets and more.
In this episode, Karen Ha, MD, explores recommendations and data on the role of NNRTIs in current practice.Listen as she gives her perspectives on:DHHS guideline recommendations on the use of NNRTI-based ARTWeight gain data from the ADVANCE study, DRIVE-AHEAD, DRIVE-FORWARD, DRIVE-SHIFT, and a multivariate analysis of weight gain on ARTKey food effects and drug–drug interaction considerations with the use of NNRTIsPresenter:Karen Ha, MDAssistant Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineCooper University HospitalCooper Medical School of Rowan UniversityCamden, New JerseyFollow along with the slides at: https://bit.ly/3G2PS2pSee the entire program at:https://bit.ly/2TXTYWx
Nesse #episodio4 o integrante rapper e designer Preto Win Mc é um dos articuladores cultural do Sarau no Kintal, faz parte do time do RPV e convida para um papo sobre músicas, rap, futebol e resenhas de rua seu aliado de milianos o Castor da Favela, ex- jogador de futebol atuou em diversos clubes paulistanos ( Santos, Mauaense, Palmeiras, etc.). Em sua trajetória conciliou a arte futebolística com a arte musical, no final dos anos 80 iniciou sua carreira musical como rapper, em meados dos anos 2000 ganhou festivais de rap da revista Rap Brasil e gravou um dos seus singles. Castor atua na parte de incentivo ao esporte, e é rotulado como uma das figuras essenciais na periferia da zona norte de São Paulo. ⚽️✊
In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on patient specific factors associated with LA CAB plus RPV failure.Listen as she gives her perspectives on:LA CAB plus RPV pharmacokinetic dataDHHS guideline recommendations on which patients can be considered for LA CAB plus RPVData from the ATLAS, FLAIR, and ATLAS-2M studies on patients with virologic failure and the factors that may have contributedPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate ProfessorPharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, Illinois Follow along with the slides at: https://bit.ly/3EfaSRXSee the entire program at: https://bit.ly/2TXTYWx
In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity and the use of NRTI-sparing regimens with discussion of the GEMINI-1 and -2 studies of DTG/3TC and the SWORD-1 and -2 studies of DTG/RPV, and safety with long-acting injectables with specific discussion of the ATLAS and FLAIR studies of LA CAB plus RPV and the CUSTOMIZE study.Presenters:Fidelia Bernice, PharmDClinical Pharmacy SpecialistInfectious DiseasesDepartment of PharmacyUniversity of Maryland Medical CenterBaltimore, MarylandAadia I. Rana, MDAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of Alabama at Birmingham1917 ClinicBirmingham, AlabamaContent based on a CME program supported by independent educational grants fromJanssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.Link to full program:https://bit.ly/3ydMtcL
In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.Listen as he gives his perspectives on:Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TCThe SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patientsReal-world experience with switching to DTG/RPV from the OPERA studyThe TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimenThe SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimenPresenter:William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaFollow along with the slides at:https://bit.ly/3n0Z8wUSee the entire program at:https://bit.ly/2TXTYWx
The 2021 election is upon us and the candidates have made their final pitch. Who's up? Who's down? What will happen on Tuesday? Democrats might have a blue wall in Northern Virginia, but Republicans smell blood. Sean Perryman is the Executive Director of the Payne Center for Social Justice Thurgood Marshall College Fund and a former Democratic candidate for Lieutenant Governor. Mike Allers is a former Republican candidate for the 50th House of Delegates district and co-host of Grand New Podcast. We analyze the statewide elections between Terry McAuliffe and Glenn Youngkin for Governor, Hala Ayala and Winsome Sears for Lieutenant Governor, and Mark Herring and Jason Miyares for Attorney General. Become a patron to hear an extended interview where Allers shares the inside story about why Winsome Sears fired her entire campaign team, and Perryman shares what he learned as a statewide candidate: https://www.patreon.com/transitionva Transcript: www.transitionva.com Facebook: https://www.facebook.com/TransitionVA/ Instagram: https://www.instagram.com/transitionvapodcast/ Twitter: www.twitter.com/transitionva Email: transitionvapodcast@gmail.com
In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data to support the management of missed CAB plus RPV injections.Listen as she gives her perspectives on:Prescribing information recommendations for managing missed injections of CAB plus RPVPharmacokinetic modeling data to support management strategies for missed injectionsData from the ATLAS and FLAIR studies on missed injections and patient outcomesPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate ProfessorPharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, Illinois Follow along with the slides at: https://bit.ly/30nJfaZSee the entire program at: https://bit.ly/2TXTYWx
In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB. This episode includes discussion of:An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWHCALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWHA Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patientsA Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEPZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TBPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/3hvRN5bContent based on an online CME program supported by an educational grant from ViiV Healthcare.
In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH. This episode includes discussion of:A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19A post hoc analysis of TANGO, evaluating the virologic and metabolic outcomes when switching to DTG/3TC vs continued 3- or 4-drug TAF-based regimensA Week 48 analysis of SALSA, demonstrating virologic efficacy and favorable safety profile of switching to DTG/3TC vs continuing a 3-drug ART regimenPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/2WZu7zmContent based on an online CME program supported by an educational grant from ViiV Healthcare.
The Salisboyz are joined by Gene Selassie and Richard Whittaker of the Thumbtacks and Screwjobs podcast to discuss the most anticipated pay-per-view of this show so far! And of course...discuss Celine Dion conspiracies? Ring the bell, it's RPV time!
In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from:The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year periodThe DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/FTC/TAF within 24 hours of HIV infection diagnosisA rapid ART start program in young PWH in New Orleans that demonstrated achievement of viral suppression in fewer than 30 days and no discontinuations due to adverse eventsThe ATLAS (including ATLAS-2M) and FLAIR studies that demonstrated efficacy and safety of long-acting injectable CAB plus RPVSWORD-1 and SWORD-2 that demonstrated switching to a 2-drug regimen of DTG plus RPV in virologically suppressed adults was safe and effectiveGEMINI-1 and GEMINI-2 that demonstrated noninferiority of DTG plus 3TC compared with DTG plus FTC/TDFTANGO that demonstrated safety and efficacy of switching to DTG/3TC in virologically suppressed adults receiving a TAF-based regimenIn addition, Dr. Sax reviews current recommendations by the DHHS, WHO, and IAS-USA regarding these emerging therapies and treatment paradigms. Presenter:Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the slides at:https://bit.ly/3zdPwm2 Content based on an online CME program supported by an educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8
In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of:The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TCThe 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TCAn extension of the FLAIR study, evaluating efficacy and safety of long-acting CAB plus RPV in treatment-naive patientsThe CUSTOMIZE study, an implementation effectiveness study that evaluated the feasibility of implementing provision of long-acting CAB plus RPV in the clinic settingThe HPTN 084 study of PrEP using CAB vs TDF plus FTC in sexually active cisgender womenThe CALIBRATE and CAPELLA studies of long-acting lenacapavir in treatment-naive and treatment-experienced patients, respectivelyIn addition, Drs. Cocohoba and Schafer discuss key considerations of these medications, including cost and acquisition logistics.Presenters:Jennifer Cocohoba, PharmDProfessorDepartment of Clinical PharmacyUniversity of California, San FranciscoSan Francisco, CaliforniaJason Schafer, PharmDProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, PennsylvaniaContent based on conference coverage of IAS 2021 with educational rant support from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp.; and ViiV Healthcare.Link to full program:https://bit.ly/3z8SBnC
Welcome back, ReplayPerViewers! This week, your favorite stable of marks takes on 2001's Insurrextion...and all the XFL scores, moral victories, and Dudley dogs there contained. Want more wrestling content? Subscribe via Patreon for bonus RPV episodes! www.patreon.com/junkfoodcinema
Crawling out of the darkest timeline, RPV returns to its regularly scheduled programming with Fancy Dan officially joining the stable and some exciting content announcements! They also discuss Whacklash 2001. Typo? Hell no. Enjoy, ladies and marks!
In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:ATLAS and FLAIR studies of long-acting injectable CAB + RPVATLAS 2M dosing studyFDA approval and DHHS statement on use of long-acting injectable ARTStudies on whether an oral lead-in is neededPresenter:Daniel R. Kuritzkes, MDChief, Division of Infectious DiseasesBrigham and Women's HospitalHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the slides at:https://bit.ly/3hNfHIISee the entire program at:https://bit.ly/2TXTYWx
Value stocks are king of the world in 2021. Which ETFs are on top? (1:15) - Value ETFs That Could Win Big (9:45) - Investing In More Niche Stock Plays (20:00) - What Has Caused This Rotation Into Value Investing And Will It Continue? (27:35) - Episode Roundup: VTV, RZV, RPV, XSVM, FOVL, AVUV, PSCE Podcast@Zacks.com
Value stocks are king of the world in 2021. Which ETFs are on top? (1:15) - Value ETFs That Could Win Big (9:45) - Investing In More Niche Stock Plays (20:00) - What Has Caused This Rotation Into Value Investing And Will It Continue? (27:35) - Episode Roundup: VTV, RZV, RPV, XSVM, FOVL, AVUV, PSCE Podcast@Zacks.com
Chris Meaney (@chrismeaney) presents episode 47 of Mean Streets powered by FTN as he welcomes Joe Pisapia (@JoePisapia17) of Fantasy Pros to the show. Joe is the author of the #1 best-selling Fantasy Black Book Series, and creator of the revolutionary player evaluation tool, Relative Position Value (RPV). Joe talks about how he incorporates RPV into his fantasy football strategy when it comes to drafting quarterbacks. They discuss their 2021 fantasy football quarterback targets and fades for the upcoming season. Is Jalen Hurts' price becoming too rich? What should we expect from Matthew Stafford in Los Angeles? How about Carson Wentz in Indianapolis, or Sam Darnold in Carolina? Meaney and Pisapia discuss rookie quarterbacks Trevor Lawrence, Trey Lance, Justin Fields and Zach Wilson, as well as sophomore quarterbacks Joe Burrow and Tua Tagovailoa. They tell you who to target and who to fade in redraft leagues, dynasty formats as Superflex leagues. They wrap up by previewing the New England Patriots from a fantasy football and betting standpoint. #FantasyFootball Fantasy Football Black Book 2021: https://www.amazon.com/dp/B095L9LWGDiTunes: https://apple.co/3jJmGBCSpotify: https://spoti.fi/34L0kezGoogle Podcasts: https://bit.ly/3efh9S1iHeart Radio: https://ihr.fm/3kMkZEMFantasy Football Rankings: https://www.ftnfantasy.com/nfl/rankingsGet a discount (10% off) at FTN Fantasy with Code “MeanStreets” https://www.ftndaily.com/pricingGet a discount (10% off) at FTN Daily with Code “MeanStreets” https://www.ftnfantasy.com/pricingGet a discount (10% off) at FTN Bets with Code “MeanStreets” https://www.ftnbets.com/pricingCheck out the FTN Network:* Daily Fantasy Sports - https://ftndaily.com* Season Long Fantasy - https://ftnfantasy.com* Sports Betting - https://ftnbets.com
How much do you know about Virginia Republican nominees Glenn Younkin, Winsome Sears, and Jason Miyares? Dr. Quentin Kidd of CNU's Wason Center and Jackie DeFusco of Richmond's News Channel 8 (WRIC) evaluate the GOP nominees for the 2021 statewide elections. They identify likely campaign issues, relative challenges and advantages for the nominees, and the likelihood that any of them might beat a Democratic opponent in November.
Governor candidate for Virginia Paul Davis comes into the Lion's Den and Matt Clifford A.K.A. Virginia Marine joins the show to give his perspective on candidates and the state of the RPV. --- Support this podcast: https://anchor.fm/j838/support
Live coverage of the Tiger Woods car accident press conference. PMS with first hand knowledge of the area where Tiger crashed his car in RPV. DVR with Vassegh after the Dodgers 1st day of full team workouts. Great Sports Talk
Em 2024, valor será de 15 salários mínimos O destaque da pauta da sessão de 22 de fevereiro foi o projeto de lei do prefeito que reduz para seis salários mínimos as sentenças judiciais consideradas de pequeno valor (RPV) nas quais o município é parte perdedora. A rigor, o projeto e as emendas decorrentes dele protagonizaram a sessão. As emendas acabaram por encontrar uma solução intermediária e escalonada.
The targeted, specialty ETFs are all the rage in 2021. Should value investors be using them to find deep value? (0:40) - Is Now The Time To Buy Into ETFs? (6:10) - Finding The Right ETF For You: Tracey’s Top Picks (17:30) - The Big Benefit of ETFs (21:50) - Episode Roundup: ARKK, QVAL, DEEP, FOVL, RPV, VBR Podcast@Zacks.com
The targeted, specialty ETFs are all the rage in 2021. Should value investors be using them to find deep value? (0:40) - Is Now The Time To Buy Into ETFs? (6:10) - Finding The Right ETF For You: Tracey’s Top Picks (17:30) - The Big Benefit of ETFs (21:50) - Episode Roundup: ARKK, QVAL, DEEP, FOVL, RPV, VBR Podcast@Zacks.com
The BullpenBros are joined by the creator of the 2021 Fantasy Baseball Black Book, Joe Pisapia. They discuss Relative Position Value, which relievers the Black Book loves, ADP values vs RPV, High Strikeout RP Options, and Explore Barrel Rates. Another can't miss episode! Follow Joe @JoePisapia17 Follow Aaron @FantasyTriage Follow Nate @NateMarcum Follow Todd @Todd_Barns Find the fellas written content at FantasyInFrames.com, the PREMIER destination for fantasy baseball relief pitching news and advice! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
RPV state central committee chooses another nominating convention to select their Governor, LG and AG candidates. See omnystudio.com/listener for privacy information.
RPV Online See omnystudio.com/listener for privacy information.
Mike and Matt sit down with Delegate Glenn Davis to discuss his 2nd run for Lieutenant Governor, his fellow LG competition, The Mandolorian, and why 2021 is make or break for the RPV.
This is an especially fun tale of pentest pwnage because it involves D.D.A.D. (Double Domain Admin Dance) and varying T.T.D.A. (Time to Domain Admin). The key takeaways I want to share from these tests are as follows: Responder.py -i eth0 -rPv is AWESOME. It can make the network rain hashes like manna from heaven! Testing the egress firewall is easy with this script. Consider this SANS article for guidance on ports to lock down. Testing for MS14-025 is easy with this site. mitm6 and ntlmrelayx can work really well together to rain shells if you follow this article. It's especially handy/focused when you create a targets.txt that looks something like this: smb://CORPAdministrator@192.168.195.2 smb://CORPAdministrator@192.168.195.3 smb://CORPbrian.admin@192.168.195.7 192.168.195.7 192.168.195.10 Then save that as your targets.txt and run ntlmrelayx with ./ntlmrelayx.py -tf /targets.txt -socks -smb2support. From there, once you get active socks connections, you can connect to them directly with a full interactive shell with something like proxychains smbclient //192.168.195.2/ -U CORP/brian.admin I ran into a weird issue with CrackMapExec where the --local-auth flag didn't seem to be working so I ended up trying the binary version and then it worked like a champ! Looking to dump lsass a "clean" way? Try RDPing in directly to the victim machine, opening up taskmgr.exe, click the Details tab, then right-click lsass.exe and choose Create dump file and bam, done. Wanna spin up a quick SMB share from your Kali box? Try smbserver.py -smb2support share /share Then, once you've pulled back the lsass.dmp file, you can rip through it easily with: pip3 install pypykatz sudo pypykatz lsa minidump lsass.dmp > lsass.txt Then comb through lsass.txt and hopefully there will be some delicious and nutritious DA creds there for you to much on!
The Challenger ousts the incumbent in Virginia's 5th Congressional District GOP Convention
Mobile Optimizations to Increase ROI Mobile Conversion rates is an important KPI. If Mobile Conversion Rate is high, then the amount of ROI & revenue generated would be high, and that's the goal. But generally, that's not the case for most e-commerce stores out there. We understand this issue, and with this video, we'll share some really helpful and proven methods of Mobile Optimizations which leads to revenue and RPV growth, with supporting study and analysis. So stick to the end and share the methods in the comments which you find most useful. ============================================================== Other eCommerce Resources: Ecommerce for Dummies: https://youtu.be/-ZAznOtqaiY What is Shopify? : https://youtu.be/DnTL1zK8RZs What is Magento? : https://youtu.be/yVtMcvlUZdg ============================================================== Subscribe to our channel: https://bit.ly/2UqyOg2 IWD Agency offers online business solutions that help maximize the retailer's consumer base with a professional website, online branding, marketing, and optimizing the overall customer retail experience. Discover the true value of your brand with professional solutions offered by experts in the online retail industry. IWD Agency YouTube channel is focused on providing quality content information, news, tips, tricks, and much more. At our YouTube channel, you'll find all the necessary information that you need to maximize your eCommerce biz. So, make sure to follow our content, share these videos, give us a thumbs up, and leave a comment below. ============================================================== Follow us on: Facebook: https://www.facebook.com/iwdagency/ Instagram: https://www.instagram.com/iwdagency/ Linkedin: https://www.linkedin.com/company/iwd-agency/ Pinterest: https://www.pinterest.com/iwdagency/ Twitter: https://twitter.com/IWDagency While you're at it, check out our blog: https://www.iwdagency.com/blogs ==============================================================
On this edition of The Predictable Revenue Podcast, co-host Collin Stewart welcomes Kyle James, VP of Sales at Zentap. Kyle is an up-and-coming sales leader – currently leading a fast growing team of AEs and SDRs – Kundalini yogi, and student of all things mindfulness. Throughout the pod, Collin and Kyle discuss how to build and harness presence, a critical life skill, in order to help bring more joy and success to your sales career (and, of course, your life). Highlights include: Kyle’s current role (00:59), why staying present is important (2:10), teaching mindfulness to your colleagues (15:04), the “RPV framework” (19:49), developing a “mindful” mindset (23:44), the sales lightning round (39:53), and cold call Collin (43:46). Show Notes: The Power of Now - https://fourminutebooks.com/the-power-of-now-summary/ Stop Future Planning - https://fs.blog/naval-ravikant/
Even value stocks had a good year in 2019. But could you buy the ETFs and walk away or did you need to be a stock picker? (1:00) - A Look Back At 2019: Index and ETF Performance Overview(11:30) - Tracey’s Top Stock Picks(20:00) - Episode Roundup: VTV, VUG, RPV, RPG, VBR, VBK, AMWD, DHI, JPM
Even value stocks had a good year in 2019. But could you buy the ETFs and walk away or did you need to be a stock picker? (1:00) - A Look Back At 2019: Index and ETF Performance Overview(11:30) - Tracey’s Top Stock Picks(20:00) - Episode Roundup: VTV, VUG, RPV, RPG, VBR, VBK, AMWD, DHI, JPM
The author of the 2019 Fantasy Blackbook, Joe Pisapia (@JoePisapia17) joins Ben Heisler (@bennyheis) to breakdown all the biggest talking points of this year's blackbook, explain the RPV (relative positional value) concept, and get into the biggest questions at each position ahead of draft season! Play Daily Fantasy Sports with NO SALARY CAPS every day at fantasysportsmarkets.com. No salaries for players means you can draft the team you want, rather than worry about who you can afford. Try us today using promo code "BLACKBOOK" for $5 on us with NO DEPOSIT REQUIRED! Enjoy the show? Review the podcast in Apple Podcasts HERE: Follow us on social media: - Twitter: - Instagram: - YouTube: - Periscope: --- Support this podcast: https://anchor.fm/fsm/support
Just the facts! We're digging into Quarterbacks. We've got lots of facts on your favorite QB's from the likes of Matthew Berry,Michael Fabiano and more! Joe Pisapia, Author of The Fantasy Black Book also joins to talk about the RPV value of the top QB's, superflex and more!Subscribe to the show on iTunes so you don't miss a minute of the off season action. If you enjoy the show, please consider giving us a rate and review on iTunes. You can also find the show on iHeartRadio, TuneIn, Stitcher and Soundcloud (as well as any podcast app you use)Join up to be a member of the army and support your boys to create more and more fantasy football content that not only wins your league, but makes you laugh! Secret Shows every month, monthly fantasy chat, giveaways, discount codes and more! Find it all at the ITL Army Page Today at www.patreon.com/itlarmyFollow the guys on Twitter @IsItTheWelsh and @BogmanSports
Stocks and Murf are back for a 3rd time this week. This time, they bring with them 5 Yard Rush Hall of Fame Guest @JoePisapia17 Author of the Amazon Best Seller: The Fantasy Black Book. We talk about the book, RPV, inventive Fantasy Draft ideas, and more fantasy ideas. Be sure to #taketheblack and join #teamblackbook here.You can listen to Joe on the Fantasy Black Book Podcast and many others.Don't forget to join the listener leagues ASAP as they are almost full.Follow us on twitter @5yardrush Follow Joe on Twitter @JoePisapia17
Paul and Justin bring Joe Pisapia on to discuss the 2019 Fantasy Black Book including the RPV system and players the system likes and dislikes.
In Advances in Project Management Part I we looked at how PMs are really investment managers. In this episode we extend the discussion to look at techniques in getting the value achieved. From risk-based analysis of the WBS to determine the effectiveness in enhancing value of each project activity, to the project leadership needed to unleash the power of the team in delivering products, to accepting and demanding that some of the accountability for project value belongs with others beyond the PM, this episode looks at the next level of getting value out of projects…beyond the PMBOK®. Project Management Point-of-View (PM-POV), a podcast series produced by the Washington DC Chapter of the Project Management Institute, allows our membership and the public at large to listen to brief and informative conversations with beltway area practioners and executives as they discuss various perspectives on project management-- its uses, its shortcomings, its changes, and its future. Listens can send comments and suggestions for topics and guests to: pm-pov@pmiwdc.org. PDU Information Earn education PDUs in the PMI Talent Triangle for each podcast you listen! Use the following information in PMI's CCRS system to register the PDUs for this podcast: PDU Category: Online or Digital Media Provider Number: C046 Activity Number: PMPOV0027 PDUs for this episode: 1 » More PM-POV Episodes About the Speakers Michael Hannan, PMP Fortezza Consulting, LLC Principal Consultant & Founder Mike Hannan is Founder & Principal Consultant at Fortezza Consulting, a management consulting firm whose innovative techniques help organizations achieve dramatic improvements in project portfolio performance. Mike brings nearly 25 years’ experience as a Consulting Executive, IT Project Portfolio and Program Manager, Process Engineer, and Software Architect, and still doesn’t know what he wants to do when he grows up. His background in Project Portfolio Management (PPM) started at NASA in the early 1990s supporting large, complex initiatives such as the International Space Station and High-Performance Computing & Communications (HPCC) programs. Since then he has managed and consulted on $500M+ project portfolios, and trained CIOs and other senior executives in Federal Civilian, Military, and Commercial environments. He is also the author of the recent best-selling book, “The CIO’s Guide to Breakthrough Project Portfolio Performance.” Tomoichi Sato ICT Management Office, JGC Corporation in Yokohama, Japan General Manager Dr. Tomoichi Sato is General Manager of ICT Management Office at JGC Corporation in Yokohama, Japan. Born in Tokyo in 1956, he majored chemical engineering at Tokyo University. He stated his carrier in JGC as a process engineer, and later became schedule engineer/project manager/PMO member in the plant engineering and the IT development fields. Since 2007, he privately started research work on PM theory and established a theoretical framework called ‘risk-based project value (RPV) analysis.’ Using this framework he has published a series of academic papers in domestic and international journals. In 2009, Japan Industrial Management Association awarded his first article as the best research paper of the year. He obtained doctor degree by his study in 2010. He also teaches PM courses at Tokyo University Graduate School and Hosei University. He wrote several Japanese books about PM, time management, advanced planning & scheduling, bill of materials (BOM) and supply chain management. Blog: http://brevis.exblog.jp/ (mainly in Japanese). Joseph A. Sopko, PMP, MSP, P3O Organizational Project Management Improvement Consultant Joseph A. Sopko, PMP, MSP, P3O is an organizational project management improvement consultant, trainer and a joint recipient of the 2013 Shingo Prize Research Award as a contributing author to The Guide to Lean Enablers for Managing Engineering Programs. With over 25 years of active project and program leadership experience in large and small organizations, Joe has served in a wide range of operational and project leadership roles both during his career in the US Navy and in the commercial sector, including eight years as an organizational improvement consultant at Siemens. For the past ten years, Joe has had considerable involvement in organizational project and program management infrastructure development and improvement initiatives including global standards development and advisory committees with PMI, APMG and ISO.
Esto es HistoCast. No es Esparta pero casi. Nos introduce en el panorama de drones y robots el profesor de ciencia política @JavierJordanE, especializado en defensa y tecnología militar y miembro del Grupo de Estudios sobre Seguridad Internacional (@grupogesi www.serguridadinternacional.es). Operando junto a él nos encontramos @LordCirencester, @vuckaner y @goyix_salduero.Secciones Historia: - ¿Qué es un dron? - 7:26 - Historia de los drones - 28:49 - Tipos de drones - 1:27:11 - Puntos flacos y peligros - 2:20:15 - Conclusión y perspectiva - 2:47:37 - Bibliografía - 2:57:27
Sean "Skipper" Moulton delves into unmanned aerial vehicles (UAVs) from a warfighter's perspective.
Footballers Mike Wright stops by to talk Jordy Nelson and the Wide Receivers. Footballguys.com and Audible podcast host Sigmund Bloom schools us on Running Backs and Strategies, and then SiriusXM and Author of the Fantasy Black Book Joe Pisapia tells us what RPV can do for drafting Quarterbacks this year. Bogman and The Welsh also have some ADP all stars for you took look at as well.Follow the guys on Twitter @IsItTheWelsh and @BogmanSportsVisit officialfantasyrings.com and pre-order a championship ring for your league today! Get 10% off a ring using the promo code #Champion. Want an even better deal? get 20% off "The Beast" if you pre-order in the month of August. Just use the Promo code #ITLRing. Subscribe to the show on iTunes NOW! Please also rate and review us! You want into one of our 8 Satellite ITL Listener Leagues with a chance to play in the championship league next year? Just go on to iTunes or Stitcher and rate and review us. Let us know you did and we'll lock you in for #SoMuchFun.Always on at InThisLeague.com
Join host Flint Engleman for his live broadcast from the 2014 Republican Party of Virginia Convention! Our show will provide guest interviews and live coverage of convention proceedings. We'll be on-location with special commentary and insight into Republican politics in Virginia. For more info about the Republican Party of Virginia Convention, go to RPV.org. Connect with The American Maverick! Follow us on Twitter @AmericanMav and check out our acclaimed blog site www.TheAmericanMaverick.com "The American Maverick Show" is a production of Maverick Media. Our host Flint Engleman broadcasts the show live from the studios of WCHV in Charlottesville, Virginia, every Sunday 8-9 PM Eastern. We are a national affiliate of Red State Talk Radio Network.
Large remotely piloted vehicles and small radio controlled aircraft, aviation news, answers to your questions, and more. Hosts: Ray Maxwell and Dr. Kiki Sanford Download or subscribe to this show at https://twit.tv/shows/maxwells-house. We invite you to read, add to, and amend our show notes. Thanks to CacheFly for the bandwidth for this show.
© 2020-2025 Ivy Podcast Discovery LLC
